OPK

OPKO Health, Inc. - Form 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2007. OPKO Health, Inc. (formerly eXegenics, Inc.) is a development-stage biopharmaceutical company focused on ophthalmic disease treatments. The company's operations are primarily driven by its lead product candidate, bevasiranib, for wet age-related macular degeneration (Wet AMD). The reporting period reflects the financial impact of a three-way reverse merger completed on March 27, 2007, involving eXegenics, Froptix Corporation, and Acuity Pharmaceuticals, Inc.

Key Financial Metrics

Debt and Liquidity: The company holds a $12.0 million line of credit with the Frost Group (related party), with $4.0 million outstanding. Additionally, a $4.0 million term loan with Horizon Financial, Inc. was assumed, with $1.7 million due in 2007 and $2.3 million in 2008. Cash used in operating activities for the six months was $6.9 million.

Material Changes vs. Prior Period

• Acquisition Impact: The most significant change is the $243.8 million non-cash charge for the write-off of acquired in-process research and development (IPR&D) from the acquisition of Acuity Pharmaceuticals. This charge drove the majority of the net loss for the six-month period.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased to $5.4 million for the six months ended June 30, 2007, compared to negligible expenses in the prior period due to the company's inception date of June 23, 2006. R&D expenses were $11.5 million for the six months.
• Capital Structure: Following the merger, the company issued significant common and preferred stock. As of June 30, 2007, 159.3 million shares of common stock were outstanding, compared to 61.8 million at year-end 2006.

Outlook, Risks, and Management Commentary

• Development Stage: The company has no revenue and expects to incur substantial losses as it advances bevasiranib through clinical trials. Enrollment for the Phase III clinical trial for bevasiranib began in July 2007, with estimated total costs of approximately $25 million.
• Liquidity Needs: Management anticipates requiring additional funding before the end of 2008. Future financing may come from private placements, public offerings, debt, or strategic collaborations. The company believes current cash and credit lines are sufficient for the next 12 months.
• Key Risks: Significant risks include the failure of clinical trials, inability to obtain regulatory approval (FDA), dependence on the success of bevasiranib, and the need for substantial additional capital. There is no assurance that profitable operations will ever be achieved.
• Investment: In April 2007, the company invested $5.0 million in Ophthalmic Technologies, Inc. (OTI), acquiring a one-third interest and an option to purchase the remaining shares.

Investor Verification Checklist

• Verify the status and enrollment progress of the Phase III clinical trial for bevasiranib initiated in July 2007.
• Confirm the terms and availability of the $12.0 million line of credit with the Frost Group and the repayment schedule for the Horizon Financial term loan.
• Assess the company's ability to raise additional capital before the end of 2008 to fund ongoing R&D and operations.
• Review the valuation and potential dilution impact of the option to acquire the remaining shares of Ophthalmic Technologies, Inc.
• Monitor the impact of stock-based compensation, which totaled $11.9 million for the six-month period, on future earnings.